Temasek Life Science Ventures Pte Ltd (TLV) and Emergent BioSolutions Inc. announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.
The broad spectrum pandemic flu vaccine is expected to be based on multiple antigens held by TLV and to be delivered as a single vaccine using Emergent's MVAtor(TM) vaccine delivery platform. Completion of this joint venture is expected in the next few weeks..............................................Full Press Release: Source